Syeda Hajra Batool*

Department of Life Sciences, University of Central Punjab, Pakistan

*Corresponding Author: Syeda Hajra Batool, Department of Life Sciences, University of Central Punjab, Pakistan.

Received: July 05, 2021; Published: July 22, 2021

Citation: Syeda Hajra Batool. “A Systematic Literature Review of Tendency of Pathogenic Diseases in the Patients of Covid-19". Acta Scientific Medical Sciences 5.8 (2021): 110-120.

Abstract

  The virus is comparable to the SARS-CoV-2 virus for several physical and pathogenic characteristics. The incidence of death and infection of seasonal influenza is lower than that of SARS-CoV-2.. The research aims to find out the tendency of the pathogenic disease in the patients of covid-19 and also to highlight the major pathogenic diseases caused by Covid-19. Researcher as well started searching for electrification: Elsevier Science Direct, Taylor and Francis, Stringer, Scopus as well as Google Scholar, to evaluate the tendency of pathogenic diseases in the patients of COVID-19 investigation already identified in open access publications or online publications, dissertations, grey literature such as abstracts, peer-reviewed journals, and unpublished reports during the period started from 1900s to 2021. In this study, study selection and extraction, publications by year, analysis of data sources, publication by context, Citation analysis, publications by context, tendency of pathogenic diseases in the patients of Covid-19, statistical analysis of covid-19 associated/pathogenic diseases have been discussed in results section. The studies included with correlation between tendency of pathogenic diseases and Covid-19 patients were analyzed. The data on the tendency of pathogenic diseases in the patients of COVID-19 were analyzed from all studies. The current research was dependent on the outcomes of the reporting studies. In order to undertake a descriptive data analysis and word frequency (keywords) have been analyzed. All statistical data were analyzed using Microsoft Excel. It is resulted that the Covid-19 patient not only affected one issue, but they also suffered from many other diseases like acute coronary artery diseases or cardiomyopathy cancer, chronic obstructive pulmonary disease (COPD) another chronic kidney disease, Sickle cell disease, weak immune system, pregnancy-related many serious issues, and many other viral and bacterial diseases.

Keywords: Pathogenesis; Covid-19; Pandemic; Tendency

Bibliography

1. Chan JF., et al. “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‐to‐person transmission: a study of a family cluster”. Lancet10223 (2020): 514-523.
2. Li Q., et al. “Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia”. The New England Journal of Medicine 382 (2020): 1199-1207.
3. Guan W., et al. “Clinical characteristics of 2019 novel coronavirus infection in China”. medRxiv 9 (2020).
4. Bauch CT., et al. “Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future”. Epidemiology 6 (2005): 791-801.
5. Zhao S., et al. “Preliminary estimation of the basic reproduction number of novel coronavirus (2019‐nCoV) in China, from 2019 to 2020: A data‐driven analysis in the early phase of the outbreak”. International Journal of Infectious Diseases 92 (2020): 214-217.
6. Tyrrell DA and Bynoe ML. “Cultivation of viruses from a high proportion of patients with colds”. Lancet 1 (1966): 76-77.
7. Global Initiative on Sharing All Influenza Data. “Phylogeny of SARS like beta coronaviruses including novel coronavirus (nCoV)”.
8. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273.
9. Rottier PJM. “The Coronaviridae”. Siddell SG, editor. 115-137. Springer Science and Business Media (2013).
10. World Health Organization. Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS) (2020).
11. World Health Organization. WHO 2019, Middle East respiratory syndrome coronavirus (MERS‐CoV) (2019).
12. Richardson P., et al. “Baricitinib as a potential treatment for 2019 nCoV acute respiratory disease”. Lancet 10223 (2020): 30-31.
13. Holshue ML., et al. “Novel Coronavirus in the United States”. The New England Journal of Medicine (2019).
14. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro”. Cell Research 30 (2020): 269-271.
15. Kono M., et al. “Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK”. Anti-viral Research 77 (2008): 150-152.
16. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
17. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA 11 (2020): 1061-1069.
18. Rodrigues Prestes T R., et al. “The anti-inflammatory potential of ACE2/angiotensin- (1-7)/Mas receptor axis: evidence from basic and clinical research”. Current Drug Targets11 (2017): 1301-1313.
19. Xiong T Y., et al. “Coronaviruses and the cardiovascular system: acute and long-term implications”. European Heart Journal19 (2020): 1798-1800.
20. Arentz M., et al. “Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State”. JAMA16 (2020): 1612-1614.
21. Hua A., et al. “Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19”. European Heart Journal22 (2020): 2130.
22. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
23. Jin JM., et al. “Gender differences in patients with COVID-19: focus on severity and mortality”. Frontiers in Public Health 8 (2020): 152.
24. Xu Z., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. The Lancet Respiratory Medicine4 (2020): 420-422.
25. Xiong T Y., et al. “Coronaviruses and the cardiovascular system: acute and long-term implications”. European Heart Journal19 (2020): 1798-1800.
26. Hua A., et al. “Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19”. European Heart Journal22 (2020): 2130.
27. Diao B., et al. “Human Kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection”. medRxiv (2020).
28. Chen D., et al. “Hypokalemia and clinical implications in patients with coronavirus disease”. medRxiv (2019).
29. Liu F., et al. “ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection”. Clinical Gastroenterology and Hepatology9 (2020): 2128.
30. Chen Y., et al. “The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes”. Infectious Diseases (except HIV/AIDS) (2020).
31. Chau T N., et al. “SARS‐associated viral hepatitis caused by a novel coronavirus: report of three cases”. Hepatology2 (2004): 302-310.
32. Han H., et al. “Prominent changes in blood coagulation of patients with SARS-CoV-2 infection”. Clinical Chemistry and Laboratory Medicine (CCLM)7 (2020): 1116-1120.
33. McAbee GN., et al. “Encephalitis associated with COVID-19 infection in an 11-year-old child”. Pediatric Neurology 109 (2020): 94.
34. Whitcroft K L and Hummel T. “Olfactory dysfunction in COVID-19: diagnosis and management”. JAMA 24 (2020): 2512-2514.
35. Poyiadji N., et al. “COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features”. Radiology 2 (2020): E119-E120.
36. Parsons T., et al. “COVID-19-associated acute disseminated encephalomyelitis (ADEM)”. Journal of Neurology 267 (2020): 2799-2802.
37. Toscano G., et al. “Guillain-Barré syndrome associated with SARS-CoV-2”. New England Journal of Medicine26 (2020): 2574-2576.
38. Mao L., et al. “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China”. JAMA Neurology6 (2020): 683-690.
39. Sedaghat Z and Karimi N. “Guillain Barre syndrome associated with COVID-19 infection: a case report”. Journal of Clinical Neuroscience 76 (2020): 233-235.
40. Pan XW., et al. “Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis”. Intensive Care Medicine6 (2020): 1114-1116.
41. Recalcati S. “Cutaneous manifestations in COVID-19: a first perspective”. Journal of the European Academy of Dermatology and Venereology 5 (2020).
42. Joob B and Wiwanitkit V. “COVID-19 can present with a rash and be mistaken for dengue”. Journal of the American Academy of Dermatology5 (2020): e177.
43. Seah I and Agrawal R. “Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals”. Ocular Immunology and Inflammation3 (2020): 391-395.
44. Toubiana J., et al. “Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study”. BMJ 369 (2020).
45. Qu R., et al. “Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19”. Journal of Medical Virology9 (2020): 1533-1541.
46. Guan W J., et al. “Clinical characteristics of coronavirus disease 2019 in China”. New England Journal of Medicine18 (2020): 1708-1720.
47. Wang K., et al. “SARS-CoV-2 invades host cells via a novel route: CD147-spike protein”. BioRxiv (2020).
48. Chen L., et al. “Ocular manifestations and clinical characteristics of 535 cases of COVID‐19 in Wuhan, China: a cross‐sectional study”. Acta Ophthalmologica 98.8 (2020): e951-e959.
49. Shi P., et al. “Impact of temperature on the dynamics of the COVID-19 outbreak in China”. Science of the Total Environment 728 (2020): 138890.
50. Huang C., et al. “Clinical features of patients infected with 2019 novel corona virus in Wuhan, China”. Lancet10223 (2020): 497-506.

Copyright: © 2021 Syeda Hajra Batool. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.